Skip to main content

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

A webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter, Instagram or LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.36
+5.88 (2.72%)
AAPL  263.38
+1.14 (0.43%)
AMD  238.81
-1.75 (-0.73%)
BAC  51.77
-0.27 (-0.53%)
GOOG  252.72
-4.30 (-1.67%)
META  732.78
+0.61 (0.08%)
MSFT  515.97
-0.82 (-0.16%)
NVDA  181.35
-1.28 (-0.70%)
ORCL  276.63
-0.55 (-0.20%)
TSLA  445.09
-2.34 (-0.52%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.